The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcome of adjuvant BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600K– compared to V600E-mutated melanoma.
 
Michael Weichenthal
Honoraria - Bristol-Myers Squibb; Immunocore; Merck Sharp & Dohme; Novartis; Regeneron; Sanofi; Sun Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sun Pharma
Research Funding - Bristol-Myers Squibb (Inst); Innate Pharma (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
 
Eva Ellebaek
Honoraria - Bristol Myers Squibb Foundation; Merck; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Merck; Pierre Fabre
 
Peter Mohr
Honoraria - Bristol-Myers Squibb; Delcat; Immunocore; Merck Sharp & Dohme; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma Advanced Research Company
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis Deutschland LTd (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sun Pharma
 
Mirna Šitum
No Relationships to Disclose
 
Joanna Mangana
Honoraria - BMS; MSD
Consulting or Advisory Role - BMS; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Pierre Fabre
Research Funding - BMS (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - L oreal; MSD; Pierre Fabre; Sun Pharma
 
Vanna Chiarion Sileni
Consulting or Advisory Role - Immunocore; Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre; Sanofi
 
Imke von Wasielewski
Consulting or Advisory Role - MSD; Sanofi/Regeneron
Travel, Accommodations, Expenses - Kyowa Kirin International; Pierre Fabre
 
Christoffer Gebhardt
Stock and Other Ownership Interests - Dermagnostix; Dermagnostix R&D
Honoraria - Almirall; Biofrontera; BMS; Delcath Systems; Immunocore; Medscape; MSD; NAOS; Novartis; Onkowissen; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Consulting or Advisory Role - BioNTech; BMS; Delcath Systems; ImCheck therapeutics; Immatics; Immunocore; Iovance Biotherapeutics; Moderna Therapeutics; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi; Skyline Diagnostics; Sun Pharma
Speakers' Bureau - Almirall; Biofrontera; BMS; Immunocore; MSD; NAOS; Novartis; Onkowissen; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Research Funding - BMS; Delcath Systems; Novartis; Regeneron
Travel, Accommodations, Expenses - BMS; Pierre Fabre; Sun Pharma
(OPTIONAL) Uncompensated Relationships - European Association of Dermato-Oncology (EADO); European Post-Chicago Melanoma / Skin Cancer Meeting; European School of Dermato-Oncology (ESDO); German Dermatologic Cooperative Oncology Group (DeCOG); Hiege Stiftung - German Skin Cancer Foundation; Melanoma World Society (MWS); Roggenbuck Stiftung; Skin Cancer Council Germany (NVKH)
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Genesis Pharma; Medison; Merck; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Genesis Pharma; Medison; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Friedegund Meier
Honoraria - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Philogen; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Philogen; Pierre Fabre; Sanofi
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; ImCheck therapeutics; Immunocore; Incyte; Italfarmaco; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Moderna Therapeutics; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Medicenna (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Delcath Systems; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - Almirall Hermal GmbH; Bristol-Myers Squibb; Delcath Systems; Immunocore; Incyte; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Regeneron; Sanofi; Sun Pharma
Research Funding - Almirall Hermal GmbH (Inst); Amgen (Inst); kyowa (Inst); Merck Serono (Inst); Regeneron (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Almirall Hermal GmbH; Pierre Fabre; Sun Pharma
 
Inge Svane
Stock and Other Ownership Interests - IO Biotech
Honoraria - BMS; Genmab; Genmab; IO Biotech; Janssen Oncology; Mendus
Consulting or Advisory Role - Genmab; IO Biotech; Mendus
Research Funding - Adaptimmune (Inst); Asgard Therapeutics (Inst); Bristol-Myers Squibb (Inst); Enara Bio (Inst); IO Biotech (Inst); TILT Biotherapeutics (Inst)
Travel, Accommodations, Expenses - MSD
 
Dirk Schadendorf
Honoraria - Agenus; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Japan; immatics; Immunocore; InflarxGmbH; IO Biotech; Iovance Biotherapeutics; Ipsen; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Skyline Diagnostics; Sun Pharma
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; immatics; Immunocore; IO Biotech; Iovance Biotherapeutics; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Replimune; Skyline Diagnostics; Sun Pharma
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; Genesis Pharmaceuticals; MSD; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Replimune (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD; Pfizer; Sanofi